ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.9 USD | -1.33% |
|
-4.17% | -22.74% |
Presenter SpeechUnknown Executive (Executives)Good day, and welcome to the Alnylam Pharmaceuti...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
16/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
149.9
USD
Average target price
220.4
USD
Spread / Average Target
+47.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.74% | 18.96B | |
| +29.03% | 48.16B | |
| -0.10% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.48% | 25.59B | |
| +9.06% | 12.92B | |
| +30.01% | 12.03B | |
| -1.51% | 11.77B | |
| +22.69% | 11.73B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Transcript : Alnylam Pharmaceuticals, Inc. - Shareholder/Analyst Call
